HUTCHMED (NASDAQ:HCM) Shares Gap Down – Should You Sell?

HUTCHMED (China) Limited (NASDAQ:HCM)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $15.01, but opened at $14.07. HUTCHMED shares last traded at $13.93, with a volume of 34,031 shares.

Analyst Ratings Changes

Separately, StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The firm has a 50 day simple moving average of $15.96 and a 200-day simple moving average of $17.68.

Institutional Trading of HUTCHMED

Large investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio bought a new stake in shares of HUTCHMED during the third quarter worth $35,000. Blue Trust Inc. grew its holdings in shares of HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after purchasing an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of HUTCHMED by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after purchasing an additional 2,321 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after purchasing an additional 564 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of HUTCHMED during the second quarter worth $213,000. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.